Skip to Main Content

Author Details

Joshua J Gagne
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
2005
271
40
PMIDPaper TitleJournal TitlePublished Year
36464785Prospective validation of a dynamic prognostic model for identifying COVID-19 patients at high risk of rapid deterioration.Pharmacoepidemiol Drug Saf2023
37213116Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.JAMA Intern Med2023
33984866Using a Simple Prescription Gap to Determine Warfarin Discontinuation Can Lead to Substantial Misclassification.Thromb Haemost2022
35835561Comparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants.Neurology2022
35788796Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE-Reply.JAMA2022
36271223Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.Dermatol Ther (Heidelb)2022
36195324Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.BMJ2022
36089808Partition testing for real-world evidence studies.Pharmacoepidemiol Drug Saf2022
35289881Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.JAMA2022
35092316Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting.Pharmacoepidemiol Drug Saf2022
35333307Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.Rheumatology (Oxford)2022
35201310Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.JAMA Netw Open2022
34424534Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies.Clin Pharmacol Ther2022
34387355Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data.Health Serv Res2022
32777229Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration.Ophthalmology2021
36218748Estimating Rebates and Other Discounts Received by Medicare Part D.JAMA Health Forum2021
33715267Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.Pharmacoepidemiol Drug Saf2021
33904111A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.Drug Saf2021
33615330A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics.Am J Epidemiol2021
34931012Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework.NPJ Digit Med2021
34129007Association of California's Prescription Drug Coupon Ban With Generic Drug Use.JAMA2021
34119078Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017.Value Health2021
34280330Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.Ann Intern Med2021
34048030Coprescription of Opioids With Other Medications and Risk of Opioid Overdose.Clin Pharmacol Ther2021
33245789Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data.Clin Pharmacol Ther2021
33358690Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.Am Heart J2021
33099844Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS).Pharmacoepidemiol Drug Saf2021
33207126Trends in Medicare Part D Inhaler Spending: 2012-2018.Ann Am Thorac Soc2021
33206339Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program.Drug Saf2021
31628857Validation of a comorbidity index for use in obstetric patients: A nationwide cohort study.Acta Obstet Gynecol Scand2020
31910271Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States.JAMA2020
31872419Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients.Clin Pharmacol Ther2020
31637696Response to "The Self-Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions".Clin Pharmacol Ther2020
32098624The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.Cardiovasc Diabetol2020
31769079Exact sequential analysis for multiple weighted binomial end points.Stat Med2020
31764277Evaluating the Impact of Increasing Allowable Inpatient Diagnoses in Medicare Claims Data.Epidemiology2020
31972062Improving measurement of binary covariates in claims data: A simulation study.Pharmacoepidemiol Drug Saf2020
33151482Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.Drugs2020
32639512Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.Am J Epidemiol2020
32835461Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists.Am J Manag Care2020
32768690Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease.Am Heart J2020
32572080Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations.Sci Rep2020
32925977Differences in characteristics of Medicare patients treated by ophthalmologists and optometrists.PLoS One2020
32897909Risk of Renal Cell Carcinoma Associated with Calcium Channel Blockers: A Nationwide Observational Study Focusing on Confounding by Indication.Epidemiology2020
32897307Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.JAMA Intern Med2020
32841986Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores.Epidemiology2020
32310250Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019.JAMA Intern Med2020
32150751Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.Ann Intern Med2020
32524701Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS).Pharmacoepidemiol Drug Saf2020
32180134Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.Drug Saf2020
  • 1 - 50 of 271

Recommended Authors

Erasmus University Medical Center
Career Start Year 2016
Number of shared co-authors 5
Department of Cardiovascular Medicine Mayo Clinic Rochester MN.
Career Start Year 2014
Number of shared co-authors 0
Erasmus University Medical Center
Career Start Year 2014
Number of shared co-authors 4
The University of Manchester, University of Manchester
Career Start Year 2013
Number of shared co-authors 4
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Career Start Year 2012
Number of shared co-authors 1
HealthPartners Institute
Career Start Year 2011
Number of shared co-authors 8
Janssen Pharmaceutical Research & Development
Career Start Year 2011
Number of shared co-authors 5
Janssen Pharmaceutical Research and Development
Career Start Year 2010
Number of shared co-authors 5
Bayer Pharma AG
Career Start Year 2009
Number of shared co-authors 1
The University of Hong Kong
Career Start Year 2008
Number of shared co-authors 4
University of California san francisco
Career Start Year 2008
Number of shared co-authors 4
University of Pennsylvania Perelman School of Medicine
Career Start Year 2007
Number of shared co-authors 2
Vanderbilt University Medical Center
Career Start Year 2004
Number of shared co-authors 1
Vanderbilt University Medical Center
Career Start Year 2004
Number of shared co-authors 3
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 3
University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 2
University of Pennsylvania Perelman School of Medicine
Career Start Year 2002
Number of shared co-authors 4
Vanderbilt University Medical Center
Career Start Year 2002
Number of shared co-authors 3
Yale School of Medicine
Career Start Year 1999
Number of shared co-authors 5
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 2
University of Washington
Career Start Year 1997
Number of shared co-authors 2
Institute of General Practice and Family Medicine, University Hospital
Career Start Year 1996
Number of shared co-authors 3
University of Dundee
Career Start Year 1996
Number of shared co-authors 4
Rush University Medical Center
Career Start Year 1995
Number of shared co-authors 4
Columbia University.
Career Start Year 1990
Number of shared co-authors 8
university of massachusetts amherst Chan Medical School
Career Start Year 1988
Number of shared co-authors 10
Weill Cornell Medical College
Career Start Year 1987
Number of shared co-authors 14
Institute of Health Policy, University of Toronto
Career Start Year 1984
Number of shared co-authors 3
The University of New Mexico
Career Start Year 1977
Number of shared co-authors 0
Center for Pharmacoepidemiology and Treatment Science, Rutgers University
Career Start Year 1970
Number of shared co-authors 10

Collaborators

Division of Pharmacoepidemiology, Brigham & Women's Hospital, Harvard Medical School
Co-authored papers 73
Brigham and Women's Hospital.
Co-authored papers 42
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 42
Harvard Medical School
Co-authored papers 24
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 22
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 19
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
Co-authored papers 15
Harvard Medical School
Co-authored papers 11
Center for Drug Evaluation and Research
Co-authored papers 10
Columbia University
Co-authored papers 9
Harvard Pilgrim Health Care Institute and Harvard Medical School
Co-authored papers 7
Center for Bioethics and Humanities, University of Colorado School of Medicine
Co-authored papers 7
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 6
Harvard T.H. Chan School of Public Health
Co-authored papers 5
Kaiser Permanente Washington Health Research Institute
Co-authored papers 5
University of Iowa, School of Public Health
Co-authored papers 5
Harvard Medical School and Harvard Pilgrim Health Care Institute
Co-authored papers 5
Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 4
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Co-authored papers 4
University of California los angeles
Co-authored papers 3
INSERM CIC-P 1, Bordeaux PharmacoEpi, Universite de Bordeaux
Co-authored papers 3
University of North Carolina at Chapel Hill
Co-authored papers 3
University of Toronto
Co-authored papers 3
City of Hope Comprehensive Cancer Center
Co-authored papers 3
Rutgers University Institute for Health, the State University of New Jersey
Co-authored papers 2
Co-authored papers 2
Vanderbilt University Medical Center
Co-authored papers 2
Heart Institute, Cincinnati Children's Hospital Medical Center
Co-authored papers 2
Clinical Epidemiology Unit, Massachusetts General Hospital
Co-authored papers 2
Co-authored papers 2